Mara G. Aspinall

• 
  pittsburgh.bizjournals.com/pittsburgh/othercities/bosto - [Cached Version]
  Published on: 10/26/2007    Last Visited: 10/31/2007  

  Mara Aspinall
  ...
  Mara Aspinall's eyes light up when she talks about hers.
  
  The energetic 45-year-old steers the discussion back to her parent company, Genzyme Corp., whenever she can.Conversations about photography, Oreo cookie collecting (more on that later) and even ex-Massachusetts governor and current U.S. presidential candidate Mitt Romney -- a former colleague of Aspinall's -- eventually head back to the company for which she works.
  
  "I have the privilege of working with a team that has taught me well," Aspinall said.
  
  As president of Genzyme's genetics division in Westborough, Aspinall is now a 10-year company veteran who has played a significant part in Genzyme's (Nasdaq: GENZ) overall growth, and she is among an emerging crop of Bay State life sciences executives who have taken both civic and industry-leadership roles as the sector has rapidly expanded in Massachusetts.
  
  Among her recent accomplishments: Aspinall was one of several executives who advised Gov.
  ...
  Aspinall has huge responsibility as head of Genzyme Genetics, which employs more than 1,500 people -- or 16 percent of Genzyme's 9,500 employees -- worldwide.
  
  The division's 300 Massachusetts employees are at the center of a booming diagnostics business that generated $140 million in sales during six months ended June 30.
  
  The genetics segment was Genzyme's fourth largest by revenue and income through the second quarter.
  
  But profits have been hard to come by, according to regulatory filings.Acquisition costs pushed Genzyme Genetics to a $227 million pretax loss last year, and Aspinall's division reported pretax losses of $3 million in 2005 and nearly $3.7 million in 2006.
  
  At the forefront
  
  Still, Genzyme Genetics, which develops and sells genetic-based diagnostic tests, is at the forefront of personalized medicine, a concept that involves specific genetic diagnoses and customized treatments for individuals.Aspinall has become a vocal spokesperson for the nascent industry, both in speeches and in articles such as a co-written piece in the October 2007 Harvard Business Review highlighting personalized medicine's promise.
  
  In person, Aspinall sounds like a fervent scientist who has seen the promise of something that can truly change medicine.She encourages her management team to meet with physicians and hospitals -- an idea she picked up during board/volunteer work for the American Cancer Society -- to see how Genzyme's products are being used.
  
  Need Assistance?More Latest News

• 
  www.massexcellence.com/AboutMax/stakeholders.html - [Cached Version]
  Published on: 3/16/2007    Last Visited: 3/16/2007  

  Mara G. Aspinall (03) PresidentGenzyme Genetics

• 
  www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/w - [Cached Version]
  Published on: 12/4/2007    Last Visited: 12/5/2007  

  patients with CLL progress rapidly," said Mara Aspinall, president of Genzyme Genetics."By proactively testing for the IgVH mutation soon after

• 
  www.cyberposium.org/cyberposium2001/highlights_bos/pane - [Cached Version]
  Published on: 11/30/2000    Last Visited: 1/2/2002  

  Mara Aspinall Panelists President , Genzyme
  ...
  Mara Aspinall, President , Genzyme
  
  This panelist is participating in the following panels:
  
  Panel The Applications of Genomics in the New Millenium
  
  When

• 
  www.bain.com/bainweb/alumni/alumni_news/alumni_news_rea - [Cached Version]
  Published on: 5/9/2001    Last Visited: 5/22/2003  

  Mara Aspinall Named President of Genzyme GeneticsPR Newswire 4/2/2001
  
  Genzyme General, a division of Genzyme Corp., announced today that Mara Aspinall has been named president of Genzyme Genetics.
  ...
  Mara Aspinall Named President of Genzyme GeneticsPR Newswire 4/2/2001
  
  Genzyme General, a division of Genzyme Corp., announced today that Mara Aspinall has been named president of Genzyme Genetics.In this role, Aspinall will direct the growth and development of Genzyme Genetics, a world leader in diagnostic testing services focused in a variety of areas including prenatal care and cancer.
  
  Aspinall will continue to serve as president of Genzyme Pharmaceuticals, a position she held while also president of the emerging technologies group.She joined Genzyme in 1997 as vice president of corporate development.
  
  "This is an exciting and important time for genetic testing and we are positioned as a market leader, continuing to bring new technology and services to customers," said Jan van Heek, executive vice president of Genzyme Corp., responsible for therapeutics, genetics, and pharmaceuticals."Mara has done an excellent job increasing the revenue of our pharmaceuticals business, shifting to higher margin products and upgrading our manufacturing facilities.I am confident she will continue to build on the successful performance of Genzyme Genetics."
  
  Genzyme Genetics, a business unit made up of over 500 employees, has genetic testing facilities in several locations throughout the world including Massachusetts, New Mexico, California, New York, and Florida.With a staff of 60 genetic counselors and medical geneticists, Genzyme Genetics provides genetic counseling at over 200 nationwide locations and also offers testing services in Japan and Germany.
  
  Prior to joining Genzyme, Aspinall was a director at the law firm Hale and Dorr LLP, and a senior consultant with Bain & Company specializing in strategic planning, business development, and marketing.She holds an MBA from Harvard Business School and an undergraduate degree from Tufts University.

• 
  www.dnapolicy.org/news.enews.article.nocategory.php?act - [Cached Version]
  Published on: 6/1/2006    Last Visited: 8/4/2008  

  The panelists were: Mara Aspinall, president of Genzyme Genetics (a division of Genzyme Corporation); Gail Javitt, director of law and policy at the Center; and Dr. Kathryn Phillips, a professor of health economics and health services research at the University of California, San Francisco.
  ...
  Mara Aspinall described how far researchers have come in recognizing and fighting disease.Fifty years ago, she said, health care providers diagnosed cancer vaguely, as "something wrong in the blood."
  ...
  Traditional medicine is evolving, Aspinall explained.Historically, health care providers have used a trial-and-error approach to therapy, using observation to prescribe a therapy, observing a patient's response, and changing or tweaking the therapy as needed.But the days of trial-and-error are gradually giving way to a more progressive approach, combining clinical evaluation and quantitative testing to improve the standard of care.
  
  The future, Aspinall said, is about predictive genetic testing.
  ...
  More information on Mara Aspinall

• 
  www.predictivebiosci.com/media_6.10.08.html - [Cached Version]
  Published on: 6/10/2008    Last Visited: 7/1/2008  

  The session will be led by Mara Aspinall, chairman of the Board of Directors for Predictive Biosciences and former president, Genzyme Genetics.

• 
  www.predictivebiosci.com/media_3.19.08.html - [Cached Version]
  Published on: 3/19/2008    Last Visited: 7/1/2008  

  "Throughout Peter's 19 years in the life sciences industry, he has demonstrated exceptional vision and leadership and we are delighted to welcome him to our team," said Mara Aspinall, chairman of Predictive Biosciences' board of directors and past president, Genzyme Genetics.

• 
  2006-in-review.maildevice.com/?page=3 - [Cached Version]
  Published on: 1/1/2006    Last Visited: 6/19/2008  

  As HBS professor Richard G. Hamermesh and Genzyme Genetics president Mara G. Aspinall write in the October issue of Harvard Business Review, "To be sure, there is no alternative to trial-and-error medicine for scores of diseases because ...

• 
  www.personalizedmedicinecoalition.org/about/leadership_ - [Cached Version]
  Published on: 2/13/2008    Last Visited: 2/13/2008  

  Mara G. AspinallVice Chair, PMCPresident, Genzyme Genetics
  
  Mara Aspinall is the President of Genzyme Genetics, a leading worldwide provider of testing and consultative services.Genzyme Genetics is a division of Genzyme Corporation, one of the world's largest biotechnology firms with more than 8,500 employees and more than $3 billion in revenue.Under Ms. Aspinall's leadership, Genzyme Genetics successfully completed and integrated four acquisitions, expanded its research and development programs, and initiated new programs for community outreach and education.Ms. Aspinall is a frequent speaker in the area of personalized medicine and convergence of diagnostics and pharmaceuticals.
  
  In addition to her current role, she has also served as president of Genzyme Pharmaceuticals and as Genzyme's vice president of corporate development.Prior to joining Genzyme, she was Director of Client Services at Hale and Dorr LLC, and was responsible for the firm's worldwide practice and development, strategic planning and marketing.
  
  She started her business career at Bain & Company, an international strategic consulting firm.At Bain, she specialized in developing and implementing business strategies for healthcare product and service companies
  
  Ms. Aspinall is also actively involved in the Boston community, with a focus on the fight against cancer and expanding educational opportunities for young children.She serves as Trustee on the Board of the Dana-Farber Cancer Institute.She earned her undergraduate degree at Tufts University and her MBA from Harvard Business School.

Page:  1 2 3 4 5